Paclitaxel Delivery to the Brain for Glioblastoma Treatment

The development of paclitaxel-loaded polymeric nanoparticles for the treatment of brain tumors was investigated. Poly(lactide-glycolide) (PLGA) nanoparticles containing 10% w/w paclitaxel with a particle size of 216 nm were administered through intranasal and intravenous routes to male Sprague-Dawley rats at a dose of 5 mg/kg. Both routes of administration showed appreciable accumulation of paclitaxel in brain tissue, liver, and kidney without any sign of toxicity. The anti-proliferative effect of the nanoparticles on glioblastoma tumor cells was comparable to that of free paclitaxel.

Automated summary

The study investigated the development of paclitaxel-loaded polymeric nanoparticles for brain tumor treatment. Poly(lactide-glycolide) (PLGA) nanoparticles with a size of 216 nm and containing 10% w/w paclitaxel were administered through intranasal and intravenous routes to rats. Both routes of administration resulted in significant accumulation of paclitaxel in brain tissue, liver, and kidney, with no observed toxicity. The anti-proliferative effect of the nanoparticles on glioblastoma tumor cells was similar to that of free paclitaxel.